We advised Immatics on the private placement of ordinary shares

Davis Polk advised Immatics N.V. in connection with its $35 million private placement of ordinary shares. All of the shares were purchased by Bristol Myers Squibb, which was granted the right to appoint a member to the Immatics Scientific Advisory Board.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know how is the foundation for its pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as its partnerships with global leaders in the pharmaceutical industry. Immatics is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

The Davis Polk capital markets team included partner Yasin Keshvargar, counsel John H. Runne and associates David Li and Christian Knoble. Partner David R. Bauer and counsel Samantha Lefland provided intellectual property advice. All members of the Davis Polk team are based in the New York office.